Restasis: Why US consumers paid billions for drug deemed ineffective in other countries

(The Dartmouth Institute for Health Policy & Clinical Practice) Restasis, a blockbuster drug sold by Allergan to treat chronic dry eye, has done $8.8 billion in US sales between 2009 and 2015, including over $2.9 billion in public monies through Medicare Part D. In an article in JAMA Internal Medicine, 'A Clear-Eyed View of Restasis and Chronic Dry Eye Disease,' Dartmouth physician-researchers Lisa Schwartz and Steven Woloshin argue that a more fundamental question we should be asking is: does R...